智通财经APP获悉，周五，Rani Therapeutics(RANI.US)飙升超265%，盘中一度熔断，股价创年内新 高，报1.76美元。消息面上，该公司宣布与中外制药Chugai达成高达10.85亿美元的合作协议，获得1000 万美元预付款，并有资格获得最高7500万美元技术转让与发展里程碑金、1亿美元销售里程碑金及个位 数特许权使用费，同时中外制药有权选择扩展至5个额外药物靶点。Rani Therapeutics主营生物制品口服 递送技术，核心平台RaniPill®专注于口服抗体及罕见病药物开发，此次合作应用于中外制药的罕见病 抗体项目，验证技术应用价值。 ...

Rani Therapeutics (Nasdaq: RANI) Makes Nasdaq Top Gainer on $1.085 Billion Pharma Collaboration News October 17, 2025- (Investorideas.com Newswire), a go-to investing platform covering biotech and medtech stocks releases a news and trading alert for Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs. The stock makes the Nasdaq top gainer list on a massive $1.085 Billion pharma deal. The stock is trading at $1.6 ...

Core Insights - Rani Therapeutics announced a strategic research collaboration with Chugai for two undisclosed molecules, which may evolve into a long-term partnership focused on oral biologic therapies for chronic diseases [2][7] - The company presented preclinical data for its oral bispecific GLP-1/GLP-2 receptor agonist, RT-114, at ENDO 2025, showing bioequivalence to subcutaneous injections in canines, indicating its potential to transform obesity treatment [2][6] - Rani Therapeutics reported a net loss of $11.2 million for Q2 2025, a decrease from $13.4 million in Q2 2024, reflecting improved financial management [10][14] Financial Results - As of June 30, 2025, Rani Therapeutics had cash, cash equivalents, and marketable securities totaling $10.2 million, down from $27.6 million at the end of 2024 [5] - Research and development expenses for Q2 2025 were $5.5 million, a decrease from $6.1 million in Q2 2024, primarily due to lower compensation costs [10][14] - General and administrative expenses for Q2 2025 were $5.0 million, down from $6.4 million in Q2 2024, attributed to reduced compensation and third-party service costs [10][14] Upcoming Milestones - The initiation of a Phase 1 clinical trial for RT-114, targeting obesity treatment, is expected in the second half of 2025 [4][6] - The company has entered into a $3.0 million registered direct offering for the sale of Class A common stock, indicating ongoing efforts to secure funding [6][7]